Literature DB >> 25036699

Clostridium difficile and the microbiota.

Anna M Seekatz, Vincent B Young.   

Abstract

Clostridium difficile infection (CDI) is the leading health care-associated illness. Both human and animal models have demonstrated the importance of the gut microbiota's capability of providing colonization resistance against C. difficile. Risk factors for disease development include antibiotic use, which disrupts the gut microbiota, leading to the loss of colonization resistance and subsequent CDI. Identification of the specific microbes capable of restoring this function remains elusive. Future studies directed at how microbial communities influence the metabolic environment may help elucidate the role of the microbiota in disease development. These findings will improve current biotherapeutics for patients with CDI, particularly those with recurrent disease.

Entities:  

Mesh:

Year:  2014        PMID: 25036699      PMCID: PMC4191019          DOI: 10.1172/JCI72336

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  97 in total

1.  Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota.

Authors:  Vincent B Young; Thomas M Schmidt
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 2.  The effect of proton pump inhibitors on the human microbiota.

Authors:  B J Vesper; A Jawdi; K W Altman; G K Haines; L Tao; J A Radosevich
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 3.  Clostridium difficile infection in the elderly.

Authors:  Jonathan M Keller; Christina M Surawicz
Journal:  Clin Geriatr Med       Date:  2014-02       Impact factor: 3.076

4.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

5.  Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982.

Authors:  B Aronsson; R Möllby; C E Nord
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

6.  The distribution of Clostridium difficile in the environment of South Wales.

Authors:  N al Saif; J S Brazier
Journal:  J Med Microbiol       Date:  1996-08       Impact factor: 2.472

7.  Immunoglobulin and non-immunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding.

Authors:  R D Rolfe; W Song
Journal:  J Med Microbiol       Date:  1995-01       Impact factor: 2.472

8.  Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.

Authors:  Kristin J Nagaro; S Tyler Phillips; Adam K Cheknis; Susan P Sambol; Walter E Zukowski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

9.  Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.

Authors:  K H Kim; R Fekety; D H Batts; D Brown; M Cudmore; J Silva; D Waters
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation.

Authors:  Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

View more
  78 in total

1.  Topical Antimicrobial Treatments Can Elicit Shifts to Resident Skin Bacterial Communities and Reduce Colonization by Staphylococcus aureus Competitors.

Authors:  Adam J SanMiguel; Jacquelyn S Meisel; Joseph Horwinski; Qi Zheng; Elizabeth A Grice
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes.

Authors:  Li Wen; Andrew Duffy
Journal:  J Nutr       Date:  2017-06-14       Impact factor: 4.798

3.  Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.

Authors:  Jemila C Kester; Douglas K Brubaker; Jason Velazquez; Charles Wright; Douglas A Lauffenburger; Linda G Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile.

Authors:  Lucie Etienne-Mesmin; Benoit Chassaing; Oluwaseyi Adekunle; Lisa M Mattei; Frederic D Bushman; Andrew T Gewirtz
Journal:  Gut       Date:  2017-02-20       Impact factor: 23.059

Review 5.  Adult vaccination.

Authors:  Kena A Swanson; H Josef Schmitt; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection.

Authors:  Harry Sokol; Sarah Jegou; Claire McQuitty; Marjolene Straub; Valentin Leducq; Cecilia Landman; Julien Kirchgesner; Guillaume Le Gall; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Mathias L Richard; Laurent Beaugerie
Journal:  Gut Microbes       Date:  2017-09-21

7.  The microbiome revolution.

Authors:  Martin J Blaser
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

8.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

Review 9.  Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?

Authors:  Laura Targownik
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

Review 10.  Antibiotics in early life and obesity.

Authors:  Laura M Cox; Martin J Blaser
Journal:  Nat Rev Endocrinol       Date:  2014-12-09       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.